Cargando…
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8(+) T cells
Expansion and differentiation of antigen-experienced PD-1(+)TCF-1(+) stem-like CD8(+) T cells into effector cells is critical for the success of immunotherapies based on PD-1 blockade(1–4). Hashimoto et al. have shown that, in chronic infections, administration of the cytokine interleukin (IL)-2 tri...
Autores principales: | Codarri Deak, Laura, Nicolini, Valeria, Hashimoto, Masao, Karagianni, Maria, Schwalie, Petra C., Lauener, Laura, Varypataki, Eleni Maria, Richard, Marine, Bommer, Esther, Sam, Johannes, Joller, Stefanie, Perro, Mario, Cremasco, Floriana, Kunz, Leo, Yanguez, Emilio, Hüsser, Tamara, Schlenker, Ramona, Mariani, Marisa, Tosevski, Vinko, Herter, Sylvia, Bacac, Marina, Waldhauer, Inja, Colombetti, Sara, Gueripel, Xavier, Wullschleger, Stephan, Tichet, Melanie, Hanahan, Douglas, Kissick, Haydn T., Leclair, Stephane, Freimoser-Grundschober, Anne, Seeber, Stefan, Teichgräber, Volker, Ahmed, Rafi, Klein, Christian, Umaña, Pablo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534752/ https://www.ncbi.nlm.nih.gov/pubmed/36171284 http://dx.doi.org/10.1038/s41586-022-05192-0 |
Ejemplares similares
-
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
por: Waldhauer, Inja, et al.
Publicado: (2021) -
Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model
por: Cremasco, Floriana, et al.
Publicado: (2021) -
Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
por: Leclercq-Cohen, Gabrielle, et al.
Publicado: (2023) -
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents
por: Herter, Sylvia, et al.
Publicado: (2016) -
Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
por: Sam, Johannes, et al.
Publicado: (2020)